SOURCE: Herborium Group, Inc.

January 04, 2011 10:27 ET

Herborium Group Attains OTC Markets' Current Information Tier

BROOK, NJ--(Marketwire - January 4, 2011) - Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced it has satisfied Pink OTC® Market requirements and now qualifies as a company with Current Information available on

Herborium, which develops, licenses and markets proprietary, all natural botanically based medicines, last week announced it has accepted the United Kingdom's (U.K.) National Association of Primary Care (NAPC) Review invitation to present an editorial on botanical alternatives for the treatment of acne and Rosacea. The periodical is read by nearly 40,000 U.K. general practitioners and dermatologists.

"I am pleased our regulatory compliance initiative has successfully elevated Herborium's OTC Market tier status to Current Information," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "We intend to continue our regulatory compliance initiative including a return on the Bulletin Board (BB). This latest achievement, together with our UK recognition, mark the most recent milestones in Herborium's continuing efforts to build investors' confidence as well as the Company's global presence." 

AcnEase®, the Company's flagship product, is a proprietary, systemically acting Botanical Therapeutic targeting acne and rosacea in both females and males of all ages. AcnEase has been proven safe and effective through rigorous clinical testing. (

"We expect this filing validation will encourage investor confidence in our public reporting as we continue executing our 'Road-to-Market Strategy' calling for revenue projections of $7.5 Million, with an ultimate goal to eventually capture 1% of the Global Natural and Alternative Treatments Market," Olszewski concluded. 

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit and 

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

Contact Information

  • Investor & Media Relations:
    Steve Haag
    (832) 577-2380